Download PDF
Thromb Haemost 1966; 16(01/02): 302-310
DOI: 10.1055/s-0038-1655564
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Distribution, Half Life Time and Placental Transfer of the Protease Inhibitor Trasylol

F. K Beller M. D.   *)
1   Department of Obstetrics and Gynecology, New York University School of Medicine
,
M. D Epstein M. D.   **)
1   Department of Obstetrics and Gynecology, New York University School of Medicine
,
H Kaller   ***)
1   Department of Obstetrics and Gynecology, New York University School of Medicine
› Author AffiliationsThis work was aided by a grant from the National Institute of Child Healt and Human Development HD 00270-05.
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

A method is described for an assay of Trasylol in the circulation. By this method it was found that Trasylol disappears rapidly from the circulation. The half life time of elimination is approximately 150 minutes. The placental barrier is not crossed by this substance.

*) Career Scientist of the Health Research Council of the City of New York under contract I 297.


**) NIH Research Trainee under contract 5-TI-HD-l 1-05.


***) Privatdozent für Pharmakologie, University of Göttingen.


 

  • References

  • 1 Anderer F. A, Hornle S. Strukturuntersuchungen anKallikrein-Inaktivator aus Rinderlunge. I. Molekulargewicht, Endgruppenanalyse und Aminosäure-Zusammensetzung. Z. Naturforsch 20: 451 1965;
    CrossrefPubMedGoogle Scholar
  • 2 Astrup T. Lung tissue as a proteolytic inhibitor. Acta physiol. scand 26: 243 1952;
    CrossrefPubMedGoogle Scholar
  • 3 Auhagen J. Verteilung und Elimination von Trasylol bei der Maus. Dissertation. Düsseldorf 1964
    PubMedGoogle Scholar
  • 4 Beck E, Schmutzler R, Duckert F. Inhibition of fibrinolysis and fibrinogenolysis in man: comparison of E-amino-caproic-acid and Kallikrein inhibitor. Thrombos. Diathes. hemorrh. (Stuttg.) 10: 106 1963;
    PubMedGoogle Scholar
  • 5 Beller F. K. Treatment of coagulation disorders in pregnancy. Clin. Obstet. Gynec 7: 372 1964;
    CrossrefPubMedGoogle Scholar
  • 6 Beller F. K, Douglas G. W, Epstein M. D. The fibrinolytic system in the newborne. (Inpress.)
    PubMedGoogle Scholar
  • 7 Johnson A. V. Tse. In: Tocantis, L. and Kazal, Blood coagulation, hemorrhage and thrombosis. Grune and Stratton; London, New York: 1965
    Google Scholar
  • 8 Kaller H. Tierexperimentelle Untersuchungen über Wirkungsdauer und Elimination von Trasylol. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak 246: 92 1963;
    PubMedGoogle Scholar
  • 9 Kraut H, Bhargava N, Schidtz F, Zimmermann H. Versuche zur Isolierung des Kallikrein -Inaktivators IV. Hoppe-Seylers Z. physiol. Chem 334: 230 1963;
    PubMedGoogle Scholar
  • 10 Kraut H, Frey E. K, Werle E. Über die Inaktivierung des Kallikreins. Hoppe-Seylers Z. physiol. Chem 192: 1 1930;
    PubMedGoogle Scholar
  • 11 Kunitz M, Northrop J. H. Isolation from beef pancreas of crystalline trypsinogen, trypsin, atrypsin inhibitor and an inhibitor-Trypsin. J. gen. Physiol 19: 991 1936;
    CrossrefPubMedGoogle Scholar
  • 12 Marx R, demente P, Werle E, Appel W. Zum Problem eines Antidots in der internen Thrombotherapie mit fibrinolytika. Blut 5: 367 1959;
    CrossrefPubMedGoogle Scholar
  • 13 Marx R. Wirkungsweise der Fibrinolytica und Antifibrinolytica. Thrombos. Diathes. hemorrh 7 (Suppl. 03) 27 1963;
    PubMedGoogle Scholar
  • 14 Werle E, Trautschold J. Bestimmung des Kallikrein-Inaktivators. ,,Trasylol” im Blut und in Organen und seine Verteilung nach Injektionen. Münch, med. Wschr 103: 773 1961;
    PubMedGoogle Scholar